These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 31626272)

  • 1. Pharmacologic and clinical assessment of kratom: An update.
    White CM
    Am J Health Syst Pharm; 2019 Nov; 76(23):1915-1925. PubMed ID: 31626272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic and clinical assessment of kratom.
    White CM
    Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Pharmacology and Legal Status of Kratom.
    Prozialeck WC
    J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kratom and Future Treatment for the Opioid Addiction and Chronic Pain: Periculo Beneficium?
    Ismail I; Wahab S; Sidi H; Das S; Lin LJ; Razali R
    Curr Drug Targets; 2019; 20(2):166-172. PubMed ID: 28443503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
    Henningfield JE; Fant RV; Wang DW
    Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy.
    Faucher MA; Morillos S; Cordova P; McNeil-Santiel J; Onisko N; Adhikari EH; Nelson DB
    J Midwifery Womens Health; 2024; 69(1):144-149. PubMed ID: 37679866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine.
    Perez J
    J Opioid Manag; 2023; 19(1):91-93. PubMed ID: 36683304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for kratom abuse in a contingency-management-based MAT setting: A case series.
    Kalin S; Dakhlalla S; Bhardwaj S
    J Opioid Manag; 2020 Sep/Oct 2020; 16(5):391-394. PubMed ID: 33226096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
    Khazaeli A; Jerry JM; Vazirian M
    J Addict Med; 2018; 12(6):493-495. PubMed ID: 30383616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.
    Prozialeck WC; Jivan JK; Andurkar SV
    J Am Osteopath Assoc; 2012 Dec; 112(12):792-9. PubMed ID: 23212430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kratom as a substitute for opioids: Results from an online survey.
    Coe MA; Pillitteri JL; Sembower MA; Gerlach KK; Henningfield JE
    Drug Alcohol Depend; 2019 Sep; 202():24-32. PubMed ID: 31284119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users.
    Singh D; Narayanan S; Vicknasingam BK; Prozialeck WC; Ramanathan S; Zainal H; Harun SN
    J Psychoactive Drugs; 2018; 50(3):266-274. PubMed ID: 29558272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrative Review of Kratom, an Emerging Psychoactive Substance With Perianesthetic Implications.
    Garmon EH; Olson K
    Anesth Analg; 2022 Dec; 135(6):1180-1188. PubMed ID: 35986675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.